Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Extracellular adenosine is elevated in cancer tissue, and it negatively regulates local immune responses. Adenosine production from extracellular ATP has attracted attention as a mechanism of regulatory T cell-mediated immune regulation. In this study, we examined whether small vesicles secreted by cancer cells, called exosomes, contribute to extracellular adenosine production and hence modulate immune effector cells indirectly. We found exosomes from diverse cancer cell types exhibit potent ATP- and 5'AMP-phosphohydrolytic activity, partly attributed to exosomally expressed CD39 and CD73, respectively. Comparable levels of activity were seen with exosomes from pleural effusions of mesothelioma patients. In such fluids, exosomes accounted for 20% of the total ATP-hydrolytic activity. Exosomes can perform both hydrolytic steps sequentially to form adenosine from ATP. This exosome-generated adenosine can trigger a cAMP response in adenosine A(2A) receptor-positive but not A(2A) receptor-negative cells. Similarly, significantly elevated cAMP was also triggered in Jurkat cells by adding exosomes with ATP but not by adding exosomes or ATP alone. A proportion of healthy donor T cells constitutively express CD39 and/or CD73. Activation of T cells by CD3/CD28 cross-linking could be inhibited by exogenously added 5'AMP in a CD73-dependent manner. However, 5'AMP converted to adenosine by exosomes inhibits T cell activation independently of T cell CD73 expression. This T cell inhibition was mediated through the adenosine A(2A) receptor. In summary, the data highlight exosome enzymic activity in the production of extracellular adenosine, and this may play a contributory role in negative modulation of T cells in the tumor environment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clayton et al. reported the expression of CD39, CD73, and eADO in MPM-derived exosome from pleural effusion, contributing to the inhibition of T cell functions [133].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [133]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766 · cited 1×
“To quantify the density of exosomes, we used a protocol similar to that previously described, based on ultracentrifugation on a linear sucrose gradient (36).”
MethodSelf-citationMembrane vesicles as conveyors of immune responses
Théry, C., Ostrowski, M., & Segura, E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2567 · Cited by 3,882 · cited 1×
“immune-activating functions, there are also accumulating data pointing to varied suppressive effects (40).”
BackgroundB lymphocytes secrete antigen-presenting vesicles.
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., & Geuze, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1161 · Cited by 3,546 · cited 1×
“The density (g/ml) of each fraction was calculated from the published table in the Beckman Ultracentrifugation catalogue as described (37).”
MethodDeaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470 · cited 5×
“These are double-positive for CD39 and CD73 in mice (12) and according to one report also in human (45).”
BackgroundInfluentialOhta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064527 · Cited by 1,286 · cited 3×
“Natural regulatory T cells of mice express both CD39 and CD73, whose coordinated enzymatic actions produce adenosine as a mechanism for immune suppression that is independent of IL-10 and TGF-b (12, 13).”
BackgroundAdenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217 · cited 1×
“mechanisms involved in adenosine formation and subsequent signaling are therefore of considerable therapeutic interest (9).”
BackgroundA2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065 · cited 1×
“Adenosine also represses immune responses in the tumor microenvironment, assisting tumor immune evasion (7, 8).”
BackgroundMalignant effusions and immunogenic tumour-derived exosomes
Andre, F., Schartz, N. E., Movassagh, M., Flament, C., Pautier, P., Morice, P., Pomel, C., Lhomme, C., Escudier, B., Le Chevalier, T., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09552-1 · Cited by 953 · cited 7×
“The cushion was collected and exosomes washed in PBS (32, 34, 35).”
MethodInfluentialExoCarta: A compendium of exosomal proteins and RNA
Mathivanan, S., & Simpson, R. J. (2009) · PROTEOMICS · doi:10.1002/pmic.200900351 · Cited by 873
Cited by
Items 101–200 of 564
Asleh, K., Dery, V., Taylor, C., Davey, M., Djeungoue‐Petga, M., & Ouellette, R. J. (2023) · Biomarker Research · doi:10.1186/s40364-023-00540-2 · Cited by 133
“In addition, free ATP in the TME can promote adenosine generation by the hydrolytic activity of EVs expressing CD39 and CD73 that induce a cAMP response in adenosine A2A receptor-positive cells resulting in T cell inhibition [280, 281].”
BackgroundBreast cancer‐derived exosomes: Tumor progression and therapeutic agents
Jabbari, N., Akbariazar, E., Feqhhi, M., Rahbarghazi, R., & Rezaie, J. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29668 · Cited by 118
Kerkelä, E., Laitinen, A., Räbinä, J., Valkonen, S., Takatalo, M., Larjo, A., Veijola, J., Lampinen, M., Siljander, P., Lehenkari, P., et al. (2016) · Stem Cells · doi:10.1002/stem.2280 · Cited by 109
Long-Term Heart Transplant Survival by Targeting the Ionotropic Purinergic Receptor P2X7
Vergani, A., Tezza, S., D’Addio, F., Fotino, C., Liu, K., Niewczas, M., Bassi, R., Molano, R. D., Kleffel, S., Petrelli, A., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.123653 · Cited by 108
“Indeed, natural ATP/P2XsR inhibitors with the ability to hydrolyze ATP are expressed on the cellular plasma membrane (eg, the ectonucleotidases CD39 and CD73).(26) Novel P2X7R inhibitors are available for human use, including periodate-oxidized ATP (oATP), CE224,535, AZD9056, and GSK1482160, thereby rendering P2X7R ta…”
BackgroundTumor-Related Exosomes Contribute to Tumor-Promoting Microenvironment: An Immunological Perspective
Chen, W., Jiang, J., Xia, W., & Huang, J. (2017) · Journal of Immunology Research · doi:10.1155/2017/1073947 · Cited by 115
“TEXs could not only have activated CD39 and CD73 on the membrane surface but also directly deliver membrane-tethered CD73 to CD39 cells, inducing the hydrolysis of ATP to adenosine and forming a T cell suppression environment [42, 71, 72].”
BackgroundHost–tumor interactions in nasopharyngeal carcinomas
Gourzonès, C., Barjon, C., & Busson, P. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.002 · Cited by 115
Ma, F., Liu, X., Zhang, Y., Tao, Y., Zhao, L., Abusalamah, H., Huffman, C., Harbison, R. A., Puram, S. V., Wang, Y., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adm7269 · Cited by 113
Functions of Cancer-Derived Extracellular Vesicles in Immunosuppression
Czernek, L., & Düchler, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0453-3 · Cited by 108
Mello, P. D. A., Coutinho‐Silva, R., & Savio, L. E. B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01526 · Cited by 115
“Exosomes derived from CD39+CD73+ tumor cells (138), Tregs (139), or MSCs (45) can also contribute to eAdo production.”
BackgroundRole of tumor-derived exosomes in cancer metastasis
Wee, I. J. Y., Syn, N. L. X., Sethi, G., Goh, B. C., & Wang, L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.10.004 · Cited by 113
Extracellular vesicles in urological malignancies: an update
Linxweiler, J., & Junker, K. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0261-8 · Cited by 117
Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers
Orentas, R. J., Yang, J. J., Wen, X., Wei, J. S., Mackall, C. L., & Khan, J. I. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00194 · Cited by 113
CD73 promotes tumor growth and metastasis
Zhang, B. (2012) · OncoImmunology · doi:10.4161/onci.1.1.18068 · Cited by 106
The Potential Biomarkers and Immunological Effects of Tumor-Derived Exosomes in Lung Cancer
Alipoor, S. D., Mortaz, E., Varahram, M., Movassaghi, M., Kraneveld, A. D., Garssen, J., & Adcock, I. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00819 · Cited by 105
“TEX contain surface CD39 and CD73, directly deliver membrane-tethered CD73 to CD39+cells and negatively modulate T cells function by production of extracellular adenosine and thus decrease the local immunity (54).”
BackgroundExtracellular vesicles and energy metabolism
Ronquist, G. K. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.10.044 · Cited by 105
Xu, S., Shao, Q.-Q., Sun, J.-T., Yang, N., Xie, Q., Wang, D.-H., Huang, Q.-B., Huang, B., Wang, X.-Y., Li, X.-G., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not067 · Cited by 102
Zhang, Z., Wang, C., Tang, L., Liu, Z., & Li, L. (2014) · Oncology Letters · doi:10.3892/ol.2014.2373 · Cited by 112
Wang, H., Lee, S., Nigro, C. L., Lattanzio, L., Merlano, M. C., Monteverde, M., Matin, R., Purdie, K. J., Mladkova, N., Bergamaschi, D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.95 · Cited by 100
“Further, NT5E-dependent production of adenosine by cancer exosomes causes suppression of T-lymphocyte function (Clayton et al, 2011).”
BackgroundChambers, A. M., & Matosevic, S. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00060 · Cited by 95
“Tumorderived exosomes were shown to express CD39 and CD73 and thus participate in the production of extracellular adenosine (Clayton et al., 2011).”
BackgroundThe Immune Regulatory Role of Adenosine in the Tumor Microenvironment
Xing, J., Zhang, J., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914928 · Cited by 277
“Studies have shown that the CD39 and CD73 carried by TEX are enzymatically active and can produce adenosine [14,15] (Figure 1).”
BackgroundCD8 + T cell exhaustion in anti‐tumour immunity: The new insights for cancer immunotherapy
Huang, Y., Jia, A., Wang, Y., & Liu, G. (2022) · Immunology · doi:10.1111/imm.13588 · Cited by 112
“Adenosine (Ado) is formed from extracellular ATP under the sequential dephosphorylation of ectonucleotidases CD39 and CD73 located on the cell surface [66].”
BackgroundSun, Y., & Liu, J. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.04.018 · Cited by 103
Exosome: A New Player in Translational Nanomedicine
Aheget, H., Tristán-Manzano, M., Mazini, L., Cortijo-Gutierrez, M., Galindo-Moreno, P., Herrera, C., Martin, F., Marchal, J. A., & Benabdellah, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082380 · Cited by 92
“According to the ISCT, while positively expressing the stromal markers CD73 and CD105, MSCs negatively express the hematopoietic markers CD14, CD34 and CD45 [112].”
Extracellular vesicles in cancer´s communication: messages we can read and how to answer
Semerádtová, A., Liegertová, M., Herma, R., Čapková, M., Brignole, C., & Zotto, G. D. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02282-1 · Cited by 103
The m TOR pathway and integrating immune regulation
Cobbold, S. P. (2013) · Immunology · doi:10.1111/imm.12162 · Cited by 107
Masoumi, E., Jafarzadeh, L., Mirzaei, H. R., Alishah, K., Fallah-Mehrjardi, K., Rostamian, H., Khakpoor-Koosheh, M., Meshkani, R., Noorbakhsh, F., & Hadjati, J. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01546-6 · Cited by 98
Extracellular ATP mediates inflammatory responses in colitis via P2 × 7 receptor signaling
Wan, P., Liu, X., Xiong, Y., Ren, Y., Jiang, C., Lü, N., Guo, Y., & Bai, A. (2016) · Scientific Reports · doi:10.1038/srep19108 · Cited by 106
Review: Microfluidics technologies for blood-based cancer liquid biopsies
Sun, Y., Haglund, T. A., Rogers, A. J., Ghanim, A. F., & Sethu, P. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2017.12.050 · Cited by 97
Hosseini‐Beheshti, E., Choi, W. W. Y., Weiswald, L., Kharmate, G., Ghaffari, M., Roshan‐Moniri, M., Hassona, M. D. H., Chan, L., Chin, M. Y., Tai, I. T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7052 · Cited by 99
“furthermore, others have reported that cancer cell derived exosomes can create an immunosuppressive microenvironment via induction of T-cell apoptosis and this was imparted via induction of adenosine [20, 69] as well as FAS-FASL ligation [70, 71].”
BackgroundTargeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy
de Leve, S., Wirsdörfer, F., & Jendrossek, V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00698 · Cited by 95
Gonçalves, F. D. C., Luk, F., Korevaar, S. S., Bouzid, R., Paz, A. H., López-Iglesias, C., Baan, C. C., Merino, A., & Hoogduijn, M. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-12121-z · Cited by 87
Canonical and non-canonical adenosinergic pathways
Ferretti, E., Horenstein, A. L., Canzonetta, C., Costa, F., & Morandi, F. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.03.007 · Cited by 97
Tumor-derived exosomes, microRNAs, and cancer immune suppression
Graner, M. W., Schnell, S. M., & Olin, M. R. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0689-6 · Cited by 93
“TEX also display active ectonucleotidases CD73 and CD39 [36], ecto-enzymes that sequentially convert extracellular ATP eventually to adenosine [37].”
Relationship between CD4 Regulatory T Cells and Anergy In Vivo
Kalekar, L. A., & Mueller, D. L. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1602031 · Cited by 91
Li, Y., Zhang, H., Chen, C., Qiao, K., Li, Z., Han, J., Han, X., Li, K., Lai, K., Liu, N., et al. (2022) · Advanced Materials · doi:10.1002/adma.202108476 · Cited by 95
Exosomes and cancer: from molecular mechanisms to clinical applications
Jafari, A., Babajani, A., Abdollahpour‐Alitappeh, M., Ahmadi, N., & Rezaei–Tavirani, M. (2021) · Medical Oncology · doi:10.1007/s12032-021-01491-0 · Cited by 93
Extracellular ATP and Adenosine in Cancer Pathogenesis and Treatment
Chiarella, A. M., Ryu, Y. K., Manji, G. A., & Rustgi, A. K. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.008 · Cited by 94
CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
Harvey, J. B., Phan, L. H., Villarreal, O. E., & Bowser, J. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00508 · Cited by 93
“Considering CD73 expression on exosomes promotes tumor immunosuppression (97, 98), it would be interesting to see if CD73 is also expressed on H.”
BackgroundMa, F., Vayalil, J., Lee, G., Wang, Y., & Peng, G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003217 · Cited by 91
Yalak, G., & Vogel, V. (2012) · Science Signaling · doi:10.1126/scisignal.2003273 · Cited by 86
“Exosomal release of ATP has been reported for cancer cells (37) but may also occur for healthy cells.”
BackgroundRoyo, F., Moreno, L., Mleczko, J., Palomo, L., González, E., Cabrera, D., Cogolludo, A. L., Pérez‐Vizcaíno, F., Liempd, S. M. V., & Falcón‐Pérez, J. M. (2017) · Scientific Reports · doi:10.1038/srep42798 · Cited by 88
Role of T cell-derived exosomes in immunoregulation
Lu, J., Wu, J., Tian, J., & Wang, S. (2018) · Immunologic Research · doi:10.1007/s12026-018-9000-0 · Cited by 87
Targeting adenosine in cancer immunotherapy: a review of recent progress
Whiteside, T. L. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1316197 · Cited by 87
“As exosomes isolated from supernatants of cell lines or from human plasma carry enzymatically active CD39 and CD73 proteins [58] and can hydrolyze eATP to adenosine in a test tube, they are expected to modulate the ADO pathway.”
BackgroundTuriello, R., Capone, M., Morretta, E., Monti, M. C., Madonna, G., Azzaro, R., Gaudio, P. D., Simeone, E., Sorrentino, A., Ascierto, P. A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004043 · Cited by 89
Morandi, F., Marimpietri, D., Horenstein, A. L., Bolzoni, M., Toscani, D., Costa, F., Castella, B., Faini, A. C., Massaia, M., Pistoia, V., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1458809 · Cited by 88
Role of extracellular vesicles in glioma progression
Quezada, C., Torres, Á., Niechi, I., Uribe, D., Contreras‐Duarte, S., Toledo, F., Martín, R. S., Gutiérrez, J., & Sobrevía, L. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.12.003 · Cited by 85
Longhi, M. S., Robson, S. C., Bernstein, S. H., Serra, S., & Deaglio, S. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0991-z · Cited by 79
“Several types of solid tumors [21, 22] and certain types of leukemia [23, 24] express the enzymatic machinery necessary to convert ATP into adenosine on their cell surface.”
BackgroundZhang, Q., An, Z.-Y., Jiang, W. G., Jin, W., & He, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115390 · Cited by 85
Wang, M., Jia, J., Cui, Y., Peng, Y., & Jiang, Y. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04359-3 · Cited by 83
“In fact, as early as 2011, studies found that CD73+ TDEVs secreted by a variety of cancer cells inhibit the immune activity of T cells in vitro [5]; in addition, high levels of CD73 expression can be detected in GBM and are related to the poor prognosis of GBM [4, 23, 24].”
BackgroundInfluentialWhiteside, T. L., Mandapathil, M., & Schuler, P. J. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711798184334 · Cited by 79
“We surmise that enzymatically-active CD39 Treg present in the human peripheral blood could similarly utilize CD73 expressed by other lymphocytes [52], exosomes [55], or vascular endothelial cells [62] to produce immunosuppressive adenosine.”
BackgroundIonizing radiation effects on the tumor microenvironment
Portella, L., & Scala, S. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.07.003 · Cited by 82
Zhang, Y., Liang, F., Zhang, D., Qi, S., & Liu, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114046 · Cited by 80
Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants
Çört, A., Özben, T., Saso, L., Luca, C. D., & Korkina, L. G. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/4251912 · Cited by 80
“showed that exosomeexpressing CD39 and CD73 suppressed T cells through adenosine production [100].”
BackgroundRueda, C. M., Jackson, C. M., & Chougnet, C. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00216 · Cited by 82
The Clinical Significance of CD73 in Cancer
Bach, N., Winzer, R., Tolosa, E., Fiedler, W., & Brauneck, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411759 · Cited by 77
“Not only cell-bound CD73 contributes to the adenosine generation in the TME, but also exosomes from different cancer types express CD73 and CD39 and show a high capacity of adenosine generation [27].”
BackgroundNovel insights into exosome-induced, tumor-associated inflammation and immunomodulation
Altevogt, P., Bretz, N. P., Ridinger, J., Utikal, J. S., & Umansky, V. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.04.008 · Cited by 78
Exosome-Mediated Signaling in Epithelial to Mesenchymal Transition and Tumor Progression
Conigliaro, A., & Cicchini, C. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm8010026 · Cited by 78
“With respect to immunomodulatory properties, TDEs exposing CD39 and CD37 on their surface can mediate T-cell suppression by extracellular adenosine production [93].”
BackgroundGeneration and Function of Non-cell-bound CD73 in Inflammation
Schneider, E., Rissiek, A., Winzer, R., Puig, B., Rissiek, B., Haag, F., Mittrücker, H., Magnus, T. U., & Tolosa, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01729 · Cited by 79
“CD73 protein and AMPase activity have been detected in EVs, in particular exosomes, derived from cancer cells (36, 71), regulatory T cells (38), mesenchymal stem cells (72), and also from human plasma (30).”
BackgroundNanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy
Zhou, Y., Yuan, J. T., Xu, K., Li, S., & Liu, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c11260 · Cited by 78
Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
Michaud, M., Sukkurwala, A. Q., Martins, I., Shen, S., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.19070 · Cited by 67
Personalized medicine and back–allogeneic exosomes for cancer immunotherapy
Samuel, M., & Gabrielsson, S. (2021) · Journal of Internal Medicine · doi:10.1111/joim.12963 · Cited by 70
Communication in tiny packages: Exosomes as means of tumor-stroma communication
Daßler-Plenker, J., Küttner, V., & Egeblad, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188340 · Cited by 70
Yao, Y., Chen, L., Wei, W., Deng, X., Ma, L., & Hao, S. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.05.058 · Cited by 73
Extracellular vesicles and immunogenic stress in cancer
Wu, Q., Zhang, H., Sun, S., Wang, L., & Sun, S. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04171-z · Cited by 76
The Role of Extracellular Vesicles in Metabolic Reprogramming of the Tumor Microenvironment
Fridman, E., Ginini, L., & Gil, Z. (2022) · Cells · doi:10.3390/cells11091433 · Cited by 71
“These phosphates are expressed by EVs from a variety of cell lines, including the bladder, colorectal, prostate, and mesothelioma cells lines [62].”
BackgroundExtracellular vesicles in cancer therapy
Wang, S. E. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.001 · Cited by 74
Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell
Yeo, R. W. Y., Chai, R., Hian, K., & Lim, S. K. (2013) · Exosomes and Microvesicles · doi:10.5772/57460 · Cited by 77
“Many cell types such as B cells [45], dendritic cells [46], mast cells [47], T cells [48], platelets [44], Schwann cells [49], tumor cells [50], mesenchymal stem cells [35], human embryonic kidney cells [51], various cancer cell lines [52] and sperms [53] are known to secrete exosomes.”
BackgroundCéspedes, P. F., Jainarayanan, A., Fernández‐Messina, L., Valvo, S., Saliba, D. G., Kurz, E., Kvalvaag, A. S., Chen, L., Ganskow, C. S. G., Colin‐York, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31160-3 · Cited by 75
Targeting adenosine and regulatory T cells in cancer immunotherapy
Churov, A. V., & Жулай, Г. А. (2021) · Human Immunology · doi:10.1016/j.humimm.2020.12.005 · Cited by 70
Selective Antimicrobial Therapies for Periodontitis: Win the “Battle and the War”
Elashiry, M., Morandini, A. C., Timothius, C. J. C., Ghaly, M., & Cutler, C. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126459 · Cited by 70
Mesenchymal Stem Cell Exosomes: The Future MSC-Based Therapy?
Lai, R. C., Yeo, R. W. Y., Tan, S. S., Zhang, B., Yin, Y., Sze, N. S. K., Choo, A. B. H., & Lim, S. K. (2012) · Humana Press eBooks · doi:10.1007/978-1-62703-200-1_3 · Cited by 79
“As exosomes were fi rst observed to be secreted by in vitro cultures of different cell types such as B cells [ 56 ] , dendritic cells [ 57 ] , mast cells [ 61 ] , T cells [ 62 ] , platelets [ 63 ] , Schwann cells [ 64 ] , tumor cells [ 65 ] , mesenchymal stem cell [ 43 ] , human embryonic kidney cell [ 66 ] , various…”
BackgroundMolecular Pathways: Tumor-Derived Microvesicles and Their Interactions with Immune Cells In Vivo
Pucci, F., & Pittet, M. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0962 · Cited by 64
Burgio, S., Noori, L., Marino Gammazza, A., Campanella, C., Logozzi, M., Fais, S., Bucchieri, F., Cappello, F., & Caruso Bavisotto, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155432 · Cited by 58
Zhou, M., Wen, Z., Cheng, F., Ma, J., Li, W., Ren, H., Sheng, Y., Dong, H., Lu, L., Hu, H., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1180485 · Cited by 68
“Beside tumor cells, most of the other cells in the effusion of our 14 patients were lymphocytes and monocytes.(53) Although our current study did not determine whether the tumor cells are the exclusive source of secreted autophgosomes, we demonstrated that IL-10-producing B cells could be induced when PBMC from health…”
Bravo, M. D. O., Carvalho, J. L., & Saldanha‐Araújo, F. (2016) · Purinergic Signalling · doi:10.1007/s11302-016-9529-0 · Cited by 70
Ludwig, N., Gillespie, D. G., Reichert, T. E., Jackson, E. K., & Whiteside, T. L. (2020) · Cancers · doi:10.3390/cancers12061602 · Cited by 67
“[13] reported that 5′-AMP converted to adenosine by CD39+/CD73+ TEX inhibited T cell activation via the adenosine A2AR independently of CD73 expression on T cells.”
BackgroundHuman γδ T ‐cell responses in infection and immunotherapy: Common mechanisms, common mediators?
Riganti, C., Massaia, M., Davey, M. S., & Eberl, M. (2012) · European Journal of Immunology · doi:10.1002/eji.201242492 · Cited by 70
Jadidi‐Niaragh, F., Ghalamfarsa, G., Memarian, A., Asgarian‐Omran, H., Razavi, S. M., Sarrafnejad, A., & Shokri, F. (2012) · Tumor Biology · doi:10.1007/s13277-012-0628-4 · Cited by 66
“Two most recent published reports showed that CD39 Treg cells could suppress generation and differentiation of Th17 cells in human [28] and animal cancer models [27].”
BackgroundThe Dichotomy of Tumor Exosomes (TEX) in Cancer Immunity: Is It All in the ConTEXt?
Kunigelis, K. E., & Graner, M. W. (2015) · Vaccines · doi:10.3390/vaccines3041019 · Cited by 69
“The effects of TEX surface CD39 and CD73 lead to an ectonucleotidase cascade that generates extracellular adenosine, which has suppressive T cell effects [130].”
BackgroundLi, P., Liu, C., Yu, Z., & Wu, M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00574 · Cited by 66
Extracellular Vesicles and Metastasis
Wang, S. E. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037275 · Cited by 66
Zhang, D. X., Vu, L. T., Ismail, N. N., Le, M. T. N., & Grimson, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.01.007 · Cited by 66
The role of the metabolite cargo of extracellular vesicles in tumor progression
Harmati, M., Bukva, M., Böröczky, T., Buzás, K., & Gyukity-Sebestyén, E. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10014-2 · Cited by 70
“Clayton and colleagues demonstrated that exosomes produced by several cancer cell types have a high capacity for ATP and 5’-AMP phosphohydrolysis, which is partly attributed to the exosomal expression of CD39 and CD73 [125].”
BackgroundRegulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints
Baghbani, E., Noorolyai, S., Shanehbandi, D., Mokhtarzadeh, A., Maleki, L. A., Khaze, V., Brunetti, O., Rahmani, S., Shadbad, M. A., Baghbanzadeh, A., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119826 · Cited by 64
Inflammatory Pathways as Promising Targets to Increase Chemotherapy Response in Bladder Cancer
Zhu, Z., Shen, Z., & Chen, X. (2012) · Mediators of Inflammation · doi:10.1155/2012/528690 · Cited by 64
“Interestingly, this T-cell inhibition was mediated through the adenosine 2A receptor [106].”
BackgroundLu, D., & Insel, P. A. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00381.2013 · Cited by 68
“Although ENTPDs do not hydrolyze nucleotide monophosphates, the sequential action of membrane-localized 5=-nucleotidases, such as CD73, on AMP, a product of ENTPD action, generates adenosine, which is an agonist for several GPCRs (A1–4 receptors) (22, 29, 32, 148).”
BackgroundNutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment
Howie, D., Waldmann, H., & Cobbold, S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00409 · Cited by 57
“Although there is evidence that this pathway is relevant to tumors escaping immune surveillance (74, 75), it remains, however, to be resolved whether adenosine is as an important component of the anti-inflammatory microenvironment within tolerated tissues.”
BackgroundVirtual Screening Identifies Novel Sulfonamide Inhibitors of ecto -5′-Nucleotidase
Ripphausen, P., Freundlieb, M., Brunschweiger, A., Zimmermann, H., Müller, C. E., & Bajorath, J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300658n · Cited by 64
A new role for extracellular vesicles: how small vesicles can feed tumors' big appetite
Lazar, I., Clement, E., Attané, C., Muller, C., & Nieto, L. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r083725 · Cited by 65
“induce a cAMP response in T cells (116).”
BackgroundThe Uptake of Extracellular Vesicles is Affected by the Differentiation Status of Myeloid Cells
Czernek, L., Chworoś, A., & Duechler, M. (2015) · Scandinavian Journal of Immunology · doi:10.1111/sji.12371 · Cited by 66
Liu, Z., Wang, Y., & Yuan, X.-H. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.1.309 · Cited by 63
“Types of tumor cells such as ovarian cancer, chronic myelogenous leukemia were demonstrated to secret functional exosomes (Cho et al., 2011; Clayton et al., 2011; Hood et al., 2011;Taverna et al., 2012).”
BackgroundCancer-derived extracellular vesicles: the ‘soil conditioner’ in breast cancer metastasis?
Chin, A. R., & Wang, S. E. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9639-8 · Cited by 64
“generation of adenosine from ATP and AMP to decrease tumoricidal CD3 T cell activity [31].”
BackgroundInhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity
Azambuja, J. H., Ludwig, N., Braganhol, E., & Whiteside, T. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225698 · Cited by 65
“ADO produced by exosomes was shown to inhibit T- cell activation through A2A R [132].”
BackgroundSierra, J., Marrugo-Ramírez, J., Rodriguez-Trujíllo, R., Mir, M., & Samitier, J. (2020) · Sensors · doi:10.3390/s20051317 · Cited by 63
“Common exosome markers, such as CD9, CD63, and CD81 [73,74], are being used for the non-specific exosome capture, either functionalized onto a channel surface or onto magnetic beads, as seen for CTCs entrapment systems, whereas cancer-associated exosomes can also be specifically secluded using EpCAM [75,76], CD24 [77]…”
BackgroundExtracellular Vesicles and Their Roles in the Tumor Immune Microenvironment
Reale, A., Khong, T. T., & Spencer, A. G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236892 · Cited by 64
Extracellular vesicles as next generation immunotherapeutics
Greening, D. W., Xu, R., Ale, A., Hagemeyer, C. E., & Chen, W. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.002 · Cited by 62
Outsmart tumor exosomes to steal the cancer initiating cell its niche
Thuma, F., & Zöller, M. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.02.011 · Cited by 67
Energy Sources for Exosome Communication in a Cancer Microenvironment
Thakur, A., Johnson, A. B., Jacobs, E., Zhang, K., Chen, J., Wei, Z., Lian, Q., & Chen, H. J. (2022) · Cancers · doi:10.3390/cancers14071698 · Cited by 61
“The augmented amount of ATP in the TME enhances the production of extracellular adenosine, a strong immunoregulator, and facilitates the immune evasion process in tumors [51].”
BackgroundTumor-Derived Extracellular Vesicles: Their Role in Immune Cells and Immunotherapy
Li, Q., Cai, S., Li, M., Salma, K. I., Zhou, X., Han, F., Chen, J., & Huyan, T. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s313912 · Cited by 59
CD39 – A bright target for cancer immunotherapy
Guo, S., Han, F., & Zhu, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113066 · Cited by 61
Metadata
- Authors
- Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z.
- Affiliations
- Velindre Cancer Centre (GB)
- Department of Pharmacology, Radiology and Oncology, School of Medicine, Cardiff University, Velindre Cancer Centre , Whitchurch, Cardiff CF14 2TL ,
- Corresponding author
- Clayton, Aled
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07
- Volume
- 187
- Issue
- 2
- Pages
- 676-683
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2153092839
- Cited by
- 540
- References
- 49
- Citations by year
- 2026: 18 · 2025: 30 · 2024: 31 · 2023: 38 · 2022: 53 · 2021: 50 · 2020: 61 · 2019: 37 · 2018: 36 · 2017: 29 · 2016: 30 · 2015: 24 · 2014: 33 · 2013: 26 · 2012: 40
- FWCI
- 23.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- tumor-derived exosomes, CD39, CD73, extracellular adenosine, ATP hydrolysis, 5'-AMP, adenosine A2A receptor, cAMP signaling, T cell activation inhibition, tumor immunosuppression, mesothelioma, extracellular vesicles
- MeSH terms
- Adenosine, Adenosine Monophosphate, Adenosine Triphosphate, Apyrase, Humans, Hydrolysis, Mesothelioma, Phosphorylation, Pleural Neoplasms, Down-Regulation, Antigens, CD, 5'-Nucleotidase, Caco-2 Cells, Jurkat Cells, Cell Line, Tumor, T-Lymphocytes, Regulatory, Exosomes, GPI-Linked Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.